KRYS Relative Valuation
KRYS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, KRYS is overvalued; if below, it's undervalued.
Historical Valuation
Krystal Biotech Inc (KRYS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -15.21. The fair price of Krystal Biotech Inc (KRYS) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：222.12
Fair
31.41
PE
1Y
3Y
5Y
Trailing
Forward
23.04
EV/EBITDA
Krystal Biotech Inc. (KRYS) has a current EV/EBITDA of 23.04. The 5-year average EV/EBITDA is 12.45. The thresholds are as follows: Strongly Undervalued below -80.61, Undervalued between -80.61 and -34.08, Fairly Valued between 58.98 and -34.08, Overvalued between 58.98 and 105.50, and Strongly Overvalued above 105.50. The current Forward EV/EBITDA of 23.04 falls within the Historic Trend Line -Fairly Valued range.
24.48
EV/EBIT
Krystal Biotech Inc. (KRYS) has a current EV/EBIT of 24.48. The 5-year average EV/EBIT is 0.59. The thresholds are as follows: Strongly Undervalued below -62.89, Undervalued between -62.89 and -31.15, Fairly Valued between 32.32 and -31.15, Overvalued between 32.32 and 64.06, and Strongly Overvalued above 64.06. The current Forward EV/EBIT of 24.48 falls within the Historic Trend Line -Fairly Valued range.
12.26
PS
Krystal Biotech Inc. (KRYS) has a current PS of 12.26. The 5-year average PS is 164.75. The thresholds are as follows: Strongly Undervalued below -994.92, Undervalued between -994.92 and -415.08, Fairly Valued between 744.59 and -415.08, Overvalued between 744.59 and 1324.42, and Strongly Overvalued above 1324.42. The current Forward PS of 12.26 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Krystal Biotech Inc. (KRYS) has a current P/OCF of 0.00. The 5-year average P/OCF is 41.01. The thresholds are as follows: Strongly Undervalued below -267.42, Undervalued between -267.42 and -113.20, Fairly Valued between 195.23 and -113.20, Overvalued between 195.23 and 349.44, and Strongly Overvalued above 349.44. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
21.27
P/FCF
Krystal Biotech Inc. (KRYS) has a current P/FCF of 21.27. The 5-year average P/FCF is -1.33. The thresholds are as follows: Strongly Undervalued below -222.70, Undervalued between -222.70 and -112.01, Fairly Valued between 109.36 and -112.01, Overvalued between 109.36 and 220.05, and Strongly Overvalued above 220.05. The current Forward P/FCF of 21.27 falls within the Historic Trend Line -Fairly Valued range.
Krystal Biotech Inc (KRYS) has a current Price-to-Book (P/B) ratio of 5.54. Compared to its 3-year average P/B ratio of 5.06 , the current P/B ratio is approximately 9.53% higher. Relative to its 5-year average P/B ratio of 4.39, the current P/B ratio is about 26.25% higher. Krystal Biotech Inc (KRYS) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -1.39%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -3.32% , the current FCF yield is about -100.00% lower.
5.65
P/B
Median3y
5.06
Median5y
4.39
2.63
FCF Yield
Median3y
-1.39
Median5y
-3.32
Competitors Valuation Multiple
The average P/S ratio for KRYS's competitors is , providing a benchmark for relative valuation. Krystal Biotech Inc Corp (KRYS) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 16.65%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of KRYS increased by 41.68% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 32.42 to 81.15.
The secondary factor is the Revenue Growth, contributed 16.65%to the performance.
Overall, the performance of KRYS in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Krystal Biotech Inc (KRYS) currently overvalued or undervalued?
What is Krystal Biotech Inc (KRYS) fair value?
How does KRYS's valuation metrics compare to the industry average?
What is the current P/B ratio for Krystal Biotech Inc (KRYS) as of Dec 05 2025?
What is the current FCF Yield for Krystal Biotech Inc (KRYS) as of Dec 05 2025?
What is the current Forward P/E ratio for Krystal Biotech Inc (KRYS) as of Dec 05 2025?